Document is current
Any future updates will be listed below
-
Authors
Sanyal, Ritabrata
Xu, Yang
Kim, Hyojin
Kramann, Rafael
Hayat, Sikander
-
Funding
Funding for this research was provided by:
RWTH Aachen University
- License Information
-
More Information
Article History
Received: 26 June 2025
Accepted: 22 April 2026
First Online: 29 April 2026
Declarations
:
: S.H. is a co-founder and shareholder of Sequantrix GmbH and has received research funding from AskBio and Novo Nordisk. R.K. is a founder, shareholder and board member of Sequantrix GmbH; is a member of the scientific advisory board of Hybridize Therapeutics; has received honoraria for advisory boards and talks from Bayer, Chugai, Pfizer, Roche, Genentech, Eli Lilly and GlaxoSmithKline; and has research funding from Travere Therapeutics, Galapagos, Novo Nordisk and AskBio. All other authors indicated that no competing interests exist.
